NO20065754L - Krystall av 1,2-dihydropyrinforbindelse og fremgangsmate for fremstilling av den samme - Google Patents

Krystall av 1,2-dihydropyrinforbindelse og fremgangsmate for fremstilling av den samme

Info

Publication number
NO20065754L
NO20065754L NO20065754A NO20065754A NO20065754L NO 20065754 L NO20065754 L NO 20065754L NO 20065754 A NO20065754 A NO 20065754A NO 20065754 A NO20065754 A NO 20065754A NO 20065754 L NO20065754 L NO 20065754L
Authority
NO
Norway
Prior art keywords
dihydropyrin
preparing
crystal
compound
same
Prior art date
Application number
NO20065754A
Other languages
English (en)
Other versions
NO339101B1 (no
Inventor
Takao Omae
Itaru Arimoto
Koichi Ito
Satoshi Nagato
Yukiko Sugaya
Yoshio Urawa
Hiroyuki Naka
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35782900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065754(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of NO20065754L publication Critical patent/NO20065754L/no
Publication of NO339101B1 publication Critical patent/NO339101B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

En krystall av 3-(2-cyanofenyl)-5-(2-pyridyl)-1-fenyl-l,2-dihydropyridin-2-on og en fremgangsmåte for fremstilling av den samme.
NO20065754A 2004-07-06 2006-12-13 Krystall av 3-(2-cyanofenyl)-5-(2-pyridyl)-1-fenyl-1,2- dihydropyridin-2-on-hydrat og fremgangsmåte for fremstilling av den samme NO339101B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004198709 2004-07-06
PCT/JP2005/012388 WO2006004107A1 (ja) 2004-07-06 2005-07-05 １，２－ジヒドロピリジン化合物の結晶およびその製造方法

Publications (2)

Publication Number Publication Date
NO20065754L true NO20065754L (no) 2007-04-04
NO339101B1 NO339101B1 (no) 2016-11-14

Family

ID=35782900

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065754A NO339101B1 (no) 2004-07-06 2006-12-13 Krystall av 3-(2-cyanofenyl)-5-(2-pyridyl)-1-fenyl-1,2- dihydropyridin-2-on-hydrat og fremgangsmåte for fremstilling av den samme

Country Status (28)

Country Link
US (3) US8304548B2 (no)
EP (3) EP2586771A3 (no)
JP (3) JP5030206B2 (no)
KR (2) KR101187218B1 (no)
CN (7) CN104402807A (no)
AT (1) ATE547405T1 (no)
AU (2) AU2005258385B2 (no)
BR (1) BRPI0510254B8 (no)
CA (2) CA2561829C (no)
CY (1) CY1114313T1 (no)
DK (1) DK1764361T3 (no)
ES (1) ES2404697T3 (no)
HR (1) HRP20130363T1 (no)
IL (2) IL180024A (no)
JO (1) JO2832B1 (no)
ME (1) ME01520B (no)
MX (1) MXPA06014458A (no)
MY (1) MY148809A (no)
NO (1) NO339101B1 (no)
NZ (1) NZ550720A (no)
PL (2) PL1764361T3 (no)
PT (1) PT1764361E (no)
RS (1) RS52752B (no)
RU (1) RU2323930C1 (no)
SI (2) SI1764361T1 (no)
TW (1) TW200606144A (no)
WO (2) WO2006004107A1 (no)
ZA (1) ZA200609274B (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2545813C (en) 2003-11-14 2011-01-04 Shanghai Genomics, Inc. The derivatives of pyridone and use thereof
ATE511843T1 (de) * 2005-04-04 2011-06-15 Eisai R&D Man Co Ltd Dihydropyridin-verbindungen für neurodegenerative erkrankungen und demenz
MX2007014114A (es) 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
AU2006328385B2 (en) * 2005-12-21 2011-08-25 Eisai R & D Management Co., Ltd. Amorphous form of 1,2-dihydropyridine compound
US20090088574A1 (en) * 2005-12-21 2009-04-02 Eisai R&D Management Co., Ltd. Crystal of 1,2-dihydropyridine compound (type iv)
WO2007126060A1 (ja) 2006-04-28 2007-11-08 Eisai R & D Management Co., Ltd １，２－ジヒドロピリジン化合物の塩
JP5318757B2 (ja) 2006-06-16 2013-10-16 ハー・ルンドベック・アクチエゼルスカベット 神経因性疼痛の治療のための、組み合わされたセロトニンおよびノルエピネフリン再取り込み阻害を有する４−［２−（４−メチルフェニルスルファニル）−フェニル］ピペリジンの結晶形
US20100099714A1 (en) * 2007-03-05 2010-04-22 Eisai R&D Management Co., Ltd. AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
CN101663256A (zh) * 2007-03-29 2010-03-03 新加坡科技研究局 生产旋光羟腈衍生物的方法
US20100130537A1 (en) * 2007-04-26 2010-05-27 Eisai R&D Management Co., Ltd Cinnamide compounds for dementia
WO2009011411A1 (en) * 2007-07-13 2009-01-22 Eisai R & D Management Co., Ltd. Ampa receptor antagonists and zonisamide for neuropathic pain
EP2164488A1 (en) * 2007-07-13 2010-03-24 Eisai R&D Management Co., Ltd. Ampa receptor antagonists and aldose reductase inhibitors for neuropathic pain
EP2164489A2 (en) * 2007-07-13 2010-03-24 Eisai R&D Management Co., Ltd. Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain
WO2009054544A1 (en) * 2007-10-26 2009-04-30 Eisai R & D Management Co., Ltd. Ampa receptor antagonists for parkinson's disease and movement disorders
JP5627574B2 (ja) * 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
CN105924386A (zh) 2009-03-25 2016-09-07 Abbvie 公司 抗病毒化合物和其用途
ITMI20111952A1 (it) 2011-10-27 2013-04-28 Italiana Sint Spa Procedimento per la prepazione di 2-metossi-5-(piridin-2-il)piridina, un intermedio del perampanel
US9096574B2 (en) 2012-01-03 2015-08-04 Mapi Pharma Ltd. Polymorphs of perampanel
ITMI20121390A1 (it) 2012-08-06 2014-02-07 F I S Fabbrica Italiana Sint P A Procedimento per la preparazione di acido 2-cianofenilboronico e suoi esteri, intermedi del perampanel o di e2040
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2015013520A1 (en) 2013-07-25 2015-01-29 IVAX International GmbH Process for the preparation of perampanel
CN104649962A (zh) * 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 吡仑帕奈倍半水合物化合物
CN103664756A (zh) * 2013-11-26 2014-03-26 苏州晶云药物科技有限公司 吡仑帕奈新晶型a及其制备方法
CN104706604A (zh) * 2013-12-12 2015-06-17 北京星昊医药股份有限公司 一种吡仑帕奈冻干口崩片及其制备方法
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
CN105085382B (zh) * 2014-05-14 2019-10-18 江苏豪森药业集团有限公司 吡仑帕奈异构体晶型及其制备方法和用途
CN103980188B (zh) * 2014-05-30 2016-01-27 浙江永宁药业股份有限公司 一种吡仑帕奈的合成方法及其中间体和中间体的合成方法
EP3259262A4 (en) 2015-02-17 2018-08-01 Mapi Pharma Limited Process and intermediates for the preparation of perampanel
WO2016147104A1 (en) * 2015-03-14 2016-09-22 Intas Pharmaceuticals Ltd. Novel process for the preparation of perampanel and its intermediates thereof
WO2016172333A1 (en) * 2015-04-21 2016-10-27 Teva Pharmaceuticals International Gmbh A solid state form of perampanel
CN105287411A (zh) * 2015-09-22 2016-02-03 美吉斯制药（厦门）有限公司 一种吡仑帕奈分散片及其制备方法
CN105906557A (zh) * 2016-03-30 2016-08-31 北京万全德众医药生物技术有限公司 2-甲氧基-5-（吡啶-2-基）吡啶的一种合成方法
CN106389367B (zh) * 2016-11-16 2020-12-18 杭州朱养心药业有限公司 吡仑帕奈包衣片剂药物组合物
CN110028442B (zh) * 2018-01-11 2020-07-17 新发药业有限公司 一种吡仑帕奈的简便制备方法
CN111801096B (zh) 2018-03-20 2024-03-05 卫材R&D管理有限公司 癫痫治疗剂
EP3560934A1 (en) 2018-04-26 2019-10-30 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure 2-cyanophenylboronic acid and esters thereof, intermediates of perampanel or of e2040
CN113226286B (zh) * 2018-12-14 2024-08-20 卫材R&D管理有限公司 1,2-二氢吡啶化合物的水基药物制剂
KR102392825B1 (ko) 2020-02-18 2022-04-29 명인제약주식회사 2-(2-옥소-1-페닐-5-피리딘-2-일피리딘-3-일)벤조니트릴과 ｌ-말릭산의 공결정 화합물 및 이의 제조 방법
WO2021240540A1 (en) 2020-05-26 2021-12-02 Celagenex Research (India) Pvt. Ltd. Novel synergistic nutritional compositions for treating seizures and chronic inflammatory diseases
CN114853666A (zh) * 2021-02-03 2022-08-05 北京万全德众医药生物技术有限公司 一种制备高纯度吡仑帕奈中间体的纯化方法
GR1010285B (el) * 2021-05-31 2022-08-24 Elpen Αε Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες περαμπανελης
KR102768044B1 (ko) * 2022-07-12 2025-02-17 이화여자대학교 산학협력단 연속 흐름 공정을 포함하는 페람파넬 유도체의 제조 방법
CN115745876B (zh) * 2022-11-01 2025-03-04 南京海纳医药科技股份有限公司 一种吡仑帕奈的制备方法
CN119060372B (zh) * 2023-06-02 2026-05-01 中国石油化工股份有限公司 交联共聚物、水凝胶及其制备方法和应用以及产品
CN118415997B (zh) * 2024-07-04 2024-10-18 山东则正医药技术有限公司 一种吡仑帕奈细粒剂的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5283761A (en) 1976-01-01 1977-07-12 Yamanouchi Pharmaceut Co Ltd Novel pyridone derivative
JPS5531072A (en) 1979-07-30 1980-03-05 Rikagaku Kenkyusho Preparation of 2-pyridone compound
DE4221583A1 (de) * 1991-11-12 1993-05-13 Bayer Ag Substituierte biphenylpyridone
IL109397A0 (en) 1993-04-28 1994-07-31 Schering Ag Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HU219777B (hu) 1993-07-02 2001-07-30 Gyógyszerkutató Intézet Kft. Optikailag aktív 1-(4-nitro-fenil)-4-metil-7,8-metiléndioxi-3,4-dihidro-5H-2,3-benzodiazepin és eljárás előállítására
DE69524246T2 (de) 1994-09-27 2002-06-27 Yamanouchi Pharmaceutical Co., Ltd. 1,2,3,4-Tetrahydroquinoxalindion Derivate und ihre Verwendung als Glutamat Rezeptor Antagonisten
US5948785A (en) 1995-04-27 1999-09-07 The Green Cross Corporation Heterocyclic amide compounds and pharmaceutical use of the same
US5935551A (en) 1995-11-15 1999-08-10 California Institute Of Technology Synthesis of zeolites by hydrothermal reaction of zeolite P1
DE19604920A1 (de) 1996-02-01 1997-08-07 Schering Ag Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
US5891871A (en) 1996-03-21 1999-04-06 Cocensys, Inc. Substituted 2,3-benzodiazepin-4-ones and the use thereof
HU9600871D0 (en) 1996-04-04 1996-05-28 Gyogyszerkutato Intezet New 2,3-benzodiazepine derivatives
PT901487E (pt) 1996-05-15 2003-08-29 Pfizer 4(3h)-quinazolinonas 2,3,6-trissubstituidas
DE19643037A1 (de) 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
ID22711A (id) 1997-02-28 1999-12-09 Pfizer Prod Inc Atropisomer dari 3-aril-4(3h)-kinazolinon dan penggunaannya sebagai antagonis reseptor-ampa
GB9708945D0 (en) * 1997-05-01 1997-06-25 Merck Sharp & Dohme Therapeutic agents
GB9711753D0 (en) 1997-06-06 1997-08-06 Merck Sharp & Dohme Therapeutic agents
WO1999031062A1 (en) 1997-12-17 1999-06-24 Shionogi & Co., Ltd. Novel pyridine compounds
CA2330304A1 (en) * 1998-04-27 1999-11-04 Centre National De La Recherche Scientifique 3-(amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of hiv related diseases
WO2000001376A2 (en) 1998-07-02 2000-01-13 Eisai Co., Ltd Pharmaceutical compositions and their uses for treatment of demyelinating disorders
DE19835918A1 (de) 1998-08-07 2000-02-10 Dresden Arzneimittel Neue antikonvulsiv wirkende 4-Amino-1-aryl-pyridin-2-one und Verfahren zu deren Herstellung
PT1300396E (pt) 2000-06-12 2009-04-20 Eisai R&D Man Co Ltd Compostos de 1,2-di-hidropiridina, processos para a sua preparação e sua utilização
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
JP4208512B2 (ja) 2002-07-23 2009-01-14 株式会社クラレ ５−（２’−ピリジル）−２−ピリドン誘導体の製造方法

Also Published As

Publication number Publication date
JP5030206B2 (ja) 2012-09-19
CA2570177A1 (en) 2006-01-12
CN101914057A (zh) 2010-12-15
NZ550720A (en) 2009-10-30
US20070142640A1 (en) 2007-06-21
CN101544599B (zh) 2012-06-06
US9045426B2 (en) 2015-06-02
US8772497B2 (en) 2014-07-08
JP5419944B2 (ja) 2014-02-19
IL180151A0 (en) 2007-06-03
EP1772450B1 (en) 2012-02-29
CN104402808A (zh) 2015-03-11
EP1764361A4 (en) 2012-05-30
CN1942443A (zh) 2007-04-04
ZA200609274B (en) 2008-06-25
PT1764361E (pt) 2013-04-23
TW200606144A (en) 2006-02-16
AU2005258385A1 (en) 2006-01-12
CN101544599A (zh) 2009-09-30
EP2586771A3 (en) 2013-07-31
WO2006004100A8 (ja) 2006-02-23
CN102382047B (zh) 2014-04-23
KR20070008617A (ko) 2007-01-17
CA2561829A1 (en) 2006-01-12
TWI346660B (no) 2011-08-11
RU2323930C1 (ru) 2008-05-10
BRPI0510254A (pt) 2007-10-23
WO2006004100A1 (ja) 2006-01-12
AU2005258378B2 (en) 2011-04-28
KR100939743B1 (ko) 2010-02-04
IL180151A (en) 2012-01-31
JPWO2006004100A1 (ja) 2008-04-24
EP1772450A4 (en) 2009-06-10
US20140142315A1 (en) 2014-05-22
CA2570177C (en) 2012-11-20
SI1772450T1 (sl) 2012-06-29
CN101914057B (zh) 2012-07-04
CN1984890A (zh) 2007-06-20
EP1764361A1 (en) 2007-03-21
CN1942443B (zh) 2012-05-09
US20100324297A1 (en) 2010-12-23
US8304548B2 (en) 2012-11-06
KR20070028459A (ko) 2007-03-12
NO339101B1 (no) 2016-11-14
AU2005258385B2 (en) 2009-11-05
BRPI0510254B1 (pt) 2019-10-29
ME01520B (me) 2014-04-20
JP2012021029A (ja) 2012-02-02
EP1772450A1 (en) 2007-04-11
ES2404697T3 (es) 2013-05-28
SI1764361T1 (sl) 2013-07-31
BRPI0510254B8 (pt) 2021-05-25
EP2586771A2 (en) 2013-05-01
CA2561829C (en) 2009-11-24
WO2006004107A1 (ja) 2006-01-12
KR101187218B1 (ko) 2012-10-02
HK1104999A1 (en) 2008-02-01
IL180024A (en) 2011-09-27
DK1764361T3 (da) 2013-05-06
CY1114313T1 (el) 2016-08-31
HRP20130363T1 (en) 2013-05-31
MXPA06014458A (es) 2007-03-01
RS52752B (sr) 2013-08-30
CN102382047A (zh) 2012-03-21
HK1102127A1 (en) 2007-11-09
CN104402807A (zh) 2015-03-11
IL180024A0 (en) 2007-05-15
MY148809A (en) 2013-05-31
AU2005258378A1 (en) 2006-01-12
EP1764361B1 (en) 2013-01-30
PL1764361T3 (pl) 2013-06-28
PL1772450T3 (pl) 2012-07-31
JPWO2006004107A1 (ja) 2008-04-24
JO2832B1 (en) 2014-09-15
ATE547405T1 (de) 2012-03-15

Similar Documents

Publication Publication Date Title
CY1114313T1 (el) Κρυσταλλος ενωσης 1,2-διϋδροπυριδινης και μεθοδος παραγωγης του ιδιου
NO20051103L (no) Indol-3-karboksamider som Glukokinase-(GK)-Aktivatorer
EA200701358A1 (ru) Кристаллические формы гидрохлорида (r)-8-хлор-1-метил-2,3,4,5-тетрагидро-1h-3-бензазепина
NO20076658L (no) Heteroarylbenzamidderivater for anvendelse som GLK aktivatorer ved behandling av diabetes
UA90720C2 (en) Heteroaroyl-substituted serine amides
ATE407938T1 (de) Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
ATE530519T1 (de) Cyclobutylaminderivate
EA200600203A1 (ru) Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2
DE602004007693D1 (de) (3-oxo-3,4-dihydro-chinoxalin-2-yl-amino)-benzamid-derivate und verwandte verbindungen als glykogen-phosphorylase-hemmer zur behandlung von diabetes und adipositas
MX2008013175A (es) Compuestos derivados de hidrazona de n-fenil-1,1,1-trifluorometasu lfonamida y su uso para controlar parasitos.
NO20082116L (no) Kjemisk fremgangsmate for fremstilling av en amido-fenoksybenzosyreforbindelse
DE602006017980D1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
NO20063576L (no) 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes
ATE446753T1 (de) Verwendung von substituierten 2-thio-3,5-dicyano- 4-phenyl-6-aminopyridinen bei der behandlung von übelkeit und erbrechen
DE50312430D1 (de) Thiazol-(bi)cycloalkyl-carboxanilide
NO20050885D0 (no) Ny fremgangsmate for syntesen av 1,3-dihydro-2H-3-benzazepin-2-onforbindelser, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
NO20084909L (no) Nye krystallformer
NO20053431D0 (no) Ny krystallinsk modifikasjon av 2-(3,5-bis-trifluormetyl-fenyl)-N-(6-(1,1-diokso-1gamma6-tiomorfolin-4-yl)-4(4-fluor-2-metyl-fenyl)-pyridin-3-yl)-N-metyl-isobutyramid.
TW200603800A (en) 4-arylmorpholin-3-one derivatives, preparation thereof and therapeutic application thereof
HK1120264A (en) 5- (phenylisoxazolylethoxy) -triazol- 3 -yl substituted pyridine compounds for the treatment of neurological, psychiatric or pain disorders
NO20071685L (no) Tricykliske adamantylamidderivater som 11-beta hydroksysteroid-dehydrogenaseinhibitorer